Monte Rosa Therapeutics annual free cash flow
2020
2021
2022
2023
2024
2025
Monte Rosa Therapeutics Free Cash Flow (FCF) History (GLUE)
Monte Rosa Therapeutics reported −$27.5M in free cash flow for fiscal 2025, a decrease of $65.5M from the previous fiscal year, with a free cash flow margin of −22.23%.
View full Monte Rosa Therapeutics company overviewMonte Rosa Therapeutics free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | −$27.5M | −$65.5M | — | −22.23% |
| 2024 | 2024-12-31 | $38.0M | $100.9M | — | +50.26% |
| 2023 | 2023-12-31 | −$62.8M | $42.5M | — | — |
| 2022 | 2022-12-31 | −$105.4M | −$36.3M | — | — |
| 2021 | 2021-12-31 | −$69.1M | −$42.7M | — | — |
| 2020 | 2020-12-31 | −$26.4M | — | — | — |
Monte Rosa Therapeutics quarterly free cash flow
Q3.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$48.8M | −$12.4M | — | −544.57% |
| Q1 2026 | 2026-03-31 | −$39.2M | $7.8M | — | −932.00% |
| Q4 2025 | 2025-12-31 | −$43.8M | −$172.5M | — | −1574.29% |
| Q3 2025 | 2025-09-30 | $99.8M | $121.2M | — | +781.46% |
| Q2 2025 | 2025-06-30 | −$36.4M | −$6.6M | — | −157.00% |
| Q1 2025 | 2025-03-31 | −$47.1M | −$7.5M | — | −55.43% |
| Q4 2024 | 2024-12-31 | $128.7M | $100.8M | +360.69% | +212.28% |
| Q3 2024 | 2024-09-30 | −$21.4M | $5.0M | — | −232.13% |
| Q2 2024 | 2024-06-30 | −$29.8M | $2.0M | — | −634.48% |
| Q1 2024 | 2024-03-31 | −$39.5M | −$7.0M | — | −3717.01% |
| Q4 2023 | 2023-12-31 | $27.9M | $59.2M | — | — |
| Q3 2023 | 2023-09-30 | −$26.4M | −$4.4M | — | — |
| Q2 2023 | 2023-06-30 | −$31.8M | −$8.8M | — | — |
| Q1 2023 | 2023-03-31 | −$32.6M | −$3.5M | — | — |
| Q4 2022 | 2022-12-31 | −$31.2M | −$14.0M | — | — |
| Q3 2022 | 2022-09-30 | −$22.0M | −$2.5M | — | — |
| Q2 2022 | 2022-06-30 | −$23.1M | −$6.8M | — | — |
| Q1 2022 | 2022-03-31 | −$29.1M | −$13.1M | — | — |
| Q4 2021 | 2021-12-31 | −$17.2M | −$9.4M | — | — |
| Q3 2021 | 2021-09-30 | −$19.5M | — | — | — |
| Q2 2021 | 2021-06-30 | −$16.3M | — | — | — |
| Q1 2021 | 2021-03-31 | −$16.0M | — | — | — |
| Q3 2020 | 2020-09-30 | −$7.8M | — | — | — |
Monte Rosa Therapeutics free cash flow growth trends
Over the last five reported fiscal years, free cash flow declined from −$26.4M to −$27.5M, a net decrease of $1.1M. Monte Rosa Therapeutics's latest reported quarter, Q2 2026, generated −$48.8M in free cash flow, a decrease of $12.4M year over year.
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Monte Rosa Therapeutics filings at SEC.gov ↗